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Review
Does the Exposure Method used in Cognitive Behavioural 
Therapy for Panic Disorder with Agoraphobia Affect 
Treatment Outcome?
SuMMARy
Panic disorder (PD) is characterized by the presence of recurrent 
unexpected panic attacks and persistent worrying about the occurrence 
of a new panic attack. 30 to 60 % of PD sufferers develop agoraphobia 
[PD(A)], a condition characterised by avoidance of anxiety-provoking 
situations, such as public transport, open or enclosed places or leaving 
the home alone. Cognitive Behavioral Therapy (CBT) is an effective 
psychological treatment for PD(A). One of its key components is 
exposure, a method for systematically approaching anxiety-provoking 
stimuli. However, up to 30% of PD(A) sufferers find traditional in 
vivo exposure (IVE) procedures too aversive. One way to increase the 
likelihood of sufferers engaging in exposure assignments is to carry 
them out in session.  In addition, new exposure methods are being 
explored as alternatives to traditional IVE, such as virtual reality 
exposure. However, little is known about how treatment outcomes 
produced by these different exposure methods compare to one another.
Aim. To review relevant literature to find out whether the exposure 
method used affects treatment outcomes in CBT for PDA. 
Method. A systematic search of the following databases was 
performed: CINAHL, PsychINFO, Cochrane Library, PsychArticles, 
Scopus, Medline, and Wed of Science. Inclusion and exclusion criteria 
were applied to the identified papers and the final set of studies was 
assessed according to methodological criteria.
Results. Eight papers were included in the review. Four papers 
were experimental studies comparing different modes of exposure, 
one paper was a retrospective naturalistic study, and three papers 
compared virtual reality exposure therapy (VRET)-enhanced CBT to 
traditional CBT. The methodological quality of the studies and the 
validity of their conclusions was found to be mixed. 
Conclusions. The review concluded that different exposure methods 
tended to produce similar results. However, some indications of IVE 
being superior to virtual reality exposure (VRE) were found. Some 
findings also indicated that the combination of therapist-assisted 
and self-led exposure might be superior to self-led exposure only. 
However, studies in this area are low in numbers and of mixed quality, 
therfore, more high-quality research in needed.
Ar ekspozicijos metodika, naudojama taikant kognityvinę ir 
elgesio terapiją panikos sutrikimo su agorafobija gydymui, turi 
įtakos terapijos efektyvumui?
Giedre zALyTE1, Julius NEvERAuSKAS1, William GOODALL2
1Behavioral Medicine Institute, Lithuanian university of Health Sciences, Palanga, Lithuania
2Department of Psychiatry, university of Dundee Medical School, Dundee, united Kingdom
SANTRAuKA
Įvadas. Panikos sutrikimas (PS) yra liga, kurios metu pacientai 
patiria stipraus nerimo (panikos) priepuolius, lydimus nuolatinio 
nerimavimo ir baimės, kad ištiks kitas priepuolis. Iki 60 proc. 
sergančiųjų patiria ir agorafobiją, t.y. baimę ir vengimą būti 
situacijose, provokuojančiose nerimą. Kognityvinė ir elgesio terapija 
(KET) yra efektyvus panikos sutrikimo su agorafobija (PSA) gydymo 
būdas, kurio vienas iš svarbiausių komponentų yra ekspozicija, t.y. 
laipsniško artėjimo prie nerimą provokuojančio stimulo metodika. 
Tačiau iki 30 proc. sergančiųjų PSA tradicinę ekspoziciją gyvai 
laiko atgrasia, todėl vienintelis būdas padidinti ekspozicijų tikimybę 
yra atlikti jas terapinių sesijų metu. Kita vertus, atsiranda ir kitų 
alternatyvų ekspozicijoms gyvai, pavyzdžiui, ekspozicija virtualioje 
realybėje, tačiau iki šiol mažai žinoma kokius terapinius rezultatus 
duoda skirtingi ekspozicijos metodai.  
Tyrimo tikslas. Atlikus atitinkančią kriterijus mokslinių publikacijų 
apžvalgą, nustatyti ar paskelbtų mokslinių tyrimų duomenys leidžia 
spręsti apie skirtingų ekspozicijos metodikų efektyvumą gydant 
panikos sutrikimą su agorafobija. 
Tyrimo metodai. Šioje literatūros apžvalgoje pateikiama sisteminio 
tyrimo, atlikto siekiant išsiaiškinti kokie terapijos rezultatai 
pasiekiami naudojant skirtingus ekspozicijos metodus,  duomenys. 
Buvo nagrinėjamos 8 įtraukimo kriterijus atitinkančios mokslinės 
publikacijos. Keturios publikacijos pateikė eksperimentinius 
duomenis, lyginant skirtingus ekspozicijos metodus. Vienas 
nagrinėtas straipsnis buvo natūralistinė studija, o trys publikacijos 
pateikė tradicinės KET ir KET, naudojant virtualę realybę palyginimo 
rezultatus. 
Rezultatai ir išvados. Apžvalgos rezultatai rodo, kad skirtingi 
ekspozicijos metodai vertinant bendrai duoda panašius terapijos 
rezultatus. Tačiau, buvo nustayta, kad esant specifinėms indikacijoms, 
ekspozicija gyvai gali būti efektyvesnė už virtualios realybės technikų 
taikymą, o su terapeutu daromos ekspozicijos derinimas su ekspozicija 
savarankiškai gali būti pranašesnis už ekspoziciją, atliekamą tik 
savarankiškai. 
Corresponding author: Giedre Zalyte,  Behavioral Medicine Institute, Lithuanian University of Health Sciences, Vyduno Str. 4, Palanga, 
Lithuania. E-mail: giedre.zalyte@gmail.com
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INTRODuCTION
Definition of Panic Disorder
Panic disorder (PD) is a common psychiatric disorder 
primarily characterised by recurrent unexpected panic attacks 
[1]. Panic attack is defined as a sudden surge of strong fear 
or intense discomfort that is characterised by four or more of 
the following symptoms: palpitations; trembling or shaking; 
sweating; feelings of choking; sensations of shortness of 
breath; abdominal distress; chest pain or discomfort, feeling 
faint; numbness; chills or heat sensations; derealisation or 
depersonalisation; fear of losing control or “going crazy”; 
and fear of dying [1]. To meet the diagnostic criteria for PD, 
at least one of the attacks needs to be followed by a period 
of no less than one month of persistent worrying about the 
occurrence of a new panic attack and its consequences; and/
or changes in individual’s behaviour aimed at avoiding future 
panic attacks [1]. 
In the American tradition, panic attacks have been 
considered to be the primary pathological phenomenon and the 
core of the disorder, agoraphobia being an avoidance behavior 
secondary to it with DSM-IV considering agoraphobia a 
residual diagnosis [2]. From the European perspective, 
however, agoraphobia had always been seen as something 
that can occur with or without panic attacks [3]. Similarly, in 
DSM-V [1], panic disorder and agoraphobia are defined as two 
separate diagnoses.
Prevalence of Panic Disorder
European studies found that the 12-month prevalence of 
PD is 1.8% [2, 4]. In the United States, the lifetime prevalence 
of PD with or without agoraphobia is estimated to be 
approximately 4.7% [5]. 
PD rates are reported to be consistently higher among 
females than males [2]. The National Comorbidity Survey 
conducted in the USA between 1990 and 1992 showed that 
women were 2.5 more likely to suffer from PD than men [6]. A 
very recent study [7] (also found that women tended to report 
more severe subjective suffering than men despite similar 
severity symptoms as measured by an observer-rated scale. 
Age of onset and typical course
The mean age of onset of PD is reported to be in the 20s 
[8], but both panic attacks and PD can also begin in childhood 
or early adolescence [3, 9]. The majority of all PD cases tend 
to report an onset before the age of 25 [2]. 
If untreated, panic disorder is usually chronic and recurrent. 
Wittchen et al. [10] reported that remission without treatment 
had been observed in 14% of cases during seven years. 
Comorbidity
 “Pure” PD appears to be rare; usually, it is highly comorbid 
with a range of other mental disorders and this pattern is 
consistent across available European community studies [2]. 
Significant associations have been found between PD and 
almost all anxiety, mood, substance misuse and somatoform 
disorders [2]. Most frequently, PD is comorbid with depressive 
disorders, followed by other anxiety disorders [2]. PD has 
also been found to be strongly associated with substance use 
disorders as well as somatoform disorders [11–13]. Comorbid 
agoraphobia is often associated with poorer treatment outcomes 
[14–16]. 
Incidence of PD co-morbid with agoraphobia has been 
reported to be between 35% and 65% [17]. To be diagnosed 
with agoraphobia, an individual must experience marked fear 
of and avoid two or more of the following situations: using 
public transportation, being in open or enclosed places, being 
outside of the home alone or being in a crowd or standing in 
line. Usually, the fear is persistent and lasts for six months or 
longer [1].
The 12-month prevalence of agoraphobia without PD in 
EU countries has been reported to be 1.3%, and the gender 
differences seem to be even larger than in PD, i.e. 3:1 [2]. The 
typical onset of Agoraphobia has also been reported to occur in 
the 20s, but slightly later than PD [2].               
Existing treatments for Panic Disorder
Studies indicate that PD sufferers usually obtain mental 
health care from GPs [5]. However, half of the patients who 
see their GPs, are estimated not to receive anxiety- specific 
treatment [18]. According to some estimates, only 10% of 
European individuals suffering from panic disorder receive 
adequate treatments, i.e. pharmacological or CBT [2].
NICE guidelines in the UK [19] specify that individuals 
suffering from PD should be offered either a psychological 
treatment in the form of CBT, a pharmacological treatment by 
antidepressant medication or guided self-help.     
An extensive meta-analysis [20] found that CBT is at least 
as effective as pharmacological treatments. Moreover, she also 
found that data on the efficacy of medication in the treatment 
of PD might be exaggerated by a publication bias, as studies 
that found non-significant results remained unpublished.  
Although various treatments by antidepressant medication 
have been found to be effective, relapse rates following 
termination of these treatments are relatively high. A 15-
year follow-up study of people originally treated for PD 
with alprazolam and imipramine, found that only 18% of the 
patients remained symptom free, while 51% of the patients still 
had anxiety attacks and received pharmacologic treatment, but 
appeared to have learned to cope with their anxiety symptoms 
and their daily functioning had improved [16]. Similar long-
term outcomes have been reported in a 7-year follow-up study 
[21] which showed that most patients were doing well, despite 
the fact that some of their anxiety symptoms persisted. 
A Swedish study [16] described changes in pharmacological 
treatment for PD in Sweden in the period between the 
late 1980s and 2003, as reflected in their study sample. At 
the end of the 1980s, 85% of the PD patients they studied 
continuously used benzodiazepines, in contrast to only 18% 
at 15-year follow-up in 2002; the opposite trend was observed 
in the use of antidepressants. However, Carpiniello et al. [22] 
reported that in the Italian PD patient cohort they had studied, 
37% of patients taking drugs regularly at follow-up were on 
benzodiazepines, 20% were on antidepressants alone, while 
43% were taking both benzodiazepines and antidepressants 
on a regular basis. In the UK, regular use of benzodiazepines 
is not recommended [19] due to their potentially damaging 
long-term effects, and the only recommended pharmacological 
interventions are either selective serotonin reuptake inhibitors 
(SSRIs) or tricyclic antidepressants (TCAs). 
Better long-term outcomes are believed to be one of the 
strengths of psychological therapies for PD. For example, 
Clark et al. [23] demonstrated that PD patients with no, mild or 
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moderate agoraphobia treated with CBT were significantly less 
likely to endorse catastrophic interpretation of bodily sensations 
than individuals treated by applied relaxation or imipramine; the 
study also demonstrated that the stronger individuals endorsed 
such beliefs, the more likely they were to relapse.        
Gould et al. [24] concluded in their meta-analysis that 
cognitive-behavioural treatments consisting of cognitive 
restructuring and interoceptive exposure showed the strongest 
effect and that CBT produced on average better results than 
pharmacological or combination treatments. Furthermore, they 
found that the gains were very well maintained at follow-up 
on average one year later, while pharmacological treatment 
showed marked slippage of gains. 
A recent meta-analysis of 124 studies [20] found that both 
CBT and BT were effective in alleviating anxiety symptoms 
when treating individuals with PD with agoraphobia. 
However, adding the cognitive element was found to be more 
effective for the associated depressive symptoms and CBT 
also had a smaller drop-out rate compared to BT (12.7% and 
18.3% respectively). CBT was found to be at least as effective 
as pharmacological treatment, and no difference was found 
between CBT only and combination treatments, consisting of 
CBT and a pharmacological intervention [20].  
CBT treatments for panic disorder
Currently, exposure based procedures and cognitive 
restructuring are considered to be the core elements in the 
treatment of PD; exposure-based techniques usually contain 
both interoceptive elements for treating panic and in vivo 
elements for agoraphobic symptoms [20]. Exposure therapy 
is defined as repeated approach toward fear-provoking stimuli 
and has been the dominant method used in CBT for anxiety 
disorders since the development of these treatments [25].  
Sharp, Power, and Swanson [26] demonstrated that both 
individual and group CBT were equally effective for PD. CBT 
mainly targets the perpetuating factors of panic disorder and 
agoraphobia, which include avoidant behaviours and cognitive 
biases [27]. 
Butler et al. [28] concluded in their review of meta-analyses 
that outcomes for the effectiveness of CT for PD are robust. 
However, psychological treatments tend to achieve better 
results the shorter the time since the onset of the disorder [29]. 
CBT has been demonstrated to be efficacious for PD without 
agoraphobia and for PD with agoraphobia when agoraphobia 
is mild to moderate [30]. However, between 26% and 40% of 
PD patients do not benefit significantly from CBT [30-31]. 
Ramnerö & Ӧst [32] reported that PD patients with moderate 
to severe agoraphobia had poorer treatment outcomes in an in 
vivo exposure-based therapy programme; the magnitude of 
change at post-treatment and follow-up was also negatively 
predicted by agoraphobic severity. 
Cognitive Model of Panic 
Clark’s [33] cognitive model of panic is derived from 
Beck’s cognitive model of depression and suggests that panic 
attacks are the result of catastrophic misinterpretation of 
certain bodily sensations and that treatment should, therefore, 
focus on correction of these interpretations. Clark’s [33] 
conceptualisation of panic acknowledges that biological 
factors may also play a role in panic attacks, especially by 
increasing individual’s vulnerability to such attacks although, 
in this model, catastrophic interpretation of bodily sensations 
is considered to be a necessary condition for the production of 
a panic attack. Further studies have demonstrated that panic 
attacks are consistently associated with anticipated physical, 
mental, or behavioural catastrophes, e.g. death, heart attack, 
loss of control or going crazy [34]. 
Behaviour-oriented Approaches
In the United States a mainly exposure-based psychological 
treatment for PD was developed by Barlow et al. [35]. 
Although the two treatment packages contain both cognitive 
and behavioural components, Clark’s model focuses primarily 
on the cognitive, while Barlow’s model relies to a larger extent 
on the behavioural techniques [36].  Nearly three decades later 
these two approaches are considered to be the gold standard of 
CBT treatments for PD and have received strongest empirical 
support [29] and both emphasize the concept of learned fear 
of bodily sensations, particularly the ones associated with 
autonomic arousal [25].  
Sánchez-Meca et al. [29] in their meta-analysis of 
psychological treatments for PD proposed a predictive model 
for differential efficacy of the specific techniques in CBT 
and found that exposure seems to be the critical component 
in CBT for panic disorder. The authors also reported that in 
vivo exposure seems to be significantly more effective than 
exposure in imagination. 
Theoretical aspects of exposure-based Treatments  
Modern exposure-based treatments for anxiety disorders 
derive from Wolpe’s [37] systematic desensitization approach 
[38]. However, although these treatments have been actively 
used for a number of decades, the theoretical understanding 
of why and how exposure works was slower to develop; and 
as a good proportion, but not all patients benefit from these 
treatments, a better understanding of the mechanism governing 
exposure-based techniques can provide new insights into why 
some individuals fail to benefit from them [38].   
One of the most influential theories aiming to explain the 
mechanisms behind exposure-based interventions is Foa and 
Kozak’s [39] emotional processing theory. Foa and Kozak [39] 
suggested that in exposure-based treatments certain indicators 
can be used to measure whether appropriate processing of fear-
related information is taking place, and these are emotional 
arousal during exposure trials, within-session habituation 
(WSH; defined as decrease in physiological reactivity and 
reported anxiety during repeated presentations of feared 
stimuli) and between-session habituation (BSH; defined as 
decrease in the initial fearful reactions to stimuli). 
Based on this theory, it was believed that levels of fear 
throughout exposure therapy reflect the levels of learning 
and are therefore very important for the therapeutic outcome; 
however, further research has produced mixed results in this 
area [40]. Furthermore, although physiological arousal usually 
declines within an exposure period, Craske et al. [40] conclude 
there is not enough data to support the idea that such declines 
indicate learning or can predict long-term improvement. 
Similarly, the authors postulate that evidence for the importance 
of BSH is limited as well and that the amount by which fear 
declines within session does not predict overall improvement. 
Craske et al. [40, 25] (propose an alternative model based 
on the Pavlovian conditioning. In this model, it is hypothesised 
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that therapeutic changes in exposure-based treatments happen 
through extinction and that inhibitory learning is central for 
the extinction to take place. Inhibitory learning is based on the 
notion that the original association between a conditional and 
unconditional stimulus (CS and US) is left intact while a new 
learning about the relationship between the US and CS takes 
place [41]. This also explains how fear can again be reactivated 
in a different context or just by the passage of time [40]. 
Craske et al. [40] argue that the data on WSH and BSH 
mirror the effects observed by Bjork & Bjork [42] when 
performance during instruction has been found unable to 
predict the actual level of learning. Tolerance of fear is currently 
believed to be more critical for the success of exposure therapy 
than the decrease in levels of fear [25, 40]. 
Craske et al. [25] hypothesize that deficits in inhibitory 
learning may not only contribute to poor response to treatment 
but also contribute to the development of the pathological fear 
or anxiety in the first place and so methods that can enhance 
inhibitory learning during exposure-based treatments can be 
very valuable [25]. Craske et al. [25] suggest that inhibitory 
learning may be enhanced by expectancy violation, deepened 
extinction [43-44], removal of safety signals as well as 
providing exposure in multiple contexts. The latter has been 
found to decrease the likelihood of fear renewal both in 
laboratory studies [45] and in a clinical study [46].
Affect labeling has also been shown to solidify inhibitory 
learning [25]. Linguistic processing has been shown to reduce 
activity in the amygdala and attenuate anxiety [47]. Craske et 
al. [25] report routinely asking their patients to describe their 
emotional states while engaging in exposure.    
Deacon et al. [48] found that interoceptive exposure was 
more effective if it continued until the individuals believed 
that the aversive consequences were 5% or less likely to 
happen. An important component of exposure is also memory 
consolidation after the exposure trial, which is encouraged 
by asking the individual to judge what they learned from the 
non-occurrence of the feared event, this way, the inhibitory 
association is strengthened [49]. 
The modes of exposure
Goldstein and Chambles [50] conceptualised bodily 
sensations as conditioned anxiety-provoking stimuli in PD 
patients and postulated the need to confront these stimuli using 
interoceptive exposure (IE). Barlow and Craske [51] define IE 
as deliberate induction of bodily sensations through various 
exercises, including head shaking, spinning, running in place 
or breathing through a straw with the aim to new learning 
experiences that may lead to a reduction of anxiety. The 
efficacy of IE in the treatment of PD is well demonstrated [52]. 
The effectiveness of in vivo exposure (IVE), or situational 
exposure, for PD with agoraphobia, has also been well 
demonstrated [53, 20, 29]. However, about 30 % of the patients 
fail to benefit from IVE because they find the procedure too 
challenging and drop out of treatment prematurely [54].
Virtual reality exposure (VRE) has been found to be 
effective in specific phobias [55–56]. Its advantages are that 
unpredictable events can be prevented, and that specific 
features can be created to address specific fears of the patient 
[57]. It has been suggested that VRE could be seen as a new 
way of applying both IE and IVE and may be useful in cases 
when patients are too afraid to confront real situations [58].       
THE AIM OF THIS REvIEW 
Despite the fact that the efficacy of exposure-based 
interventions for PD is well established, the data on whether 
certain modes of exposure delivery lead to better outcomes are 
scarce and mixed [59]. For example, Williams & Falbo [60] 
reported mixed results on whether the presence of the therapist 
improves the outcomes of IVE. Schumacher et al. [61] reported 
that not only patients but also therapists experience elevated 
levels of stress during IVE.  
On the other hand, both IE and IVE are clinically feasible 
techniques that most mental health practitioners can implement 
in their practice. Therefore, more consistent data on what is most 
likely to help this particular client group could be beneficial. 
This systematic review will attempt to answer the question 
whether application of certain modes of exposure is more likely 
to produce positive treatment outcomes in PD(A) patients.  
METHOD 
Initial search strategy
A search of electronic databases: CINAHL, Cochrane 
Library, PsycInfo, PsychArticles, Scopus, Medline and Web of 
Science was made using the search terms below:
1. “Panic“ and “Exposure”
2. “Panic disorder” and “Exposure”
3. “Exposure” or “Exposure-based” and “panic disorder” 
or “panic” not “social phobia” or “social anxiety disorder” not 
“PTSD” 
4. “Panic disorder” and “agoraphobia” not “social 
phobia” not “PTSD” not “trauma”
The search period was limited to 1980–2016. 1980 was 
chosen as the start year because that year the diagnosis of PD 
was introduced in DSM-III [62].    
The initial searches in the listed databases produced 1790 
papers. Titles revealed that many of the papers were not relevant 
and were removed, reducing the number to 457. The abstracts 
of these were examined to determine their relevance. Based 
on the information provided in the abstracts 428 papers were 
removed, and 29 papers were retained for full-text examination. 
Additional searches
Initial searches produced several meta-analyses and 
reviews on virtual reality exposure for anxiety disorders 
[63–65, 56, 66–67)]. References in these meta-analyses and 
reviews and the selected full-text papers were examined. Six 
published experts in the area were contacted by e-mail. These 
searches produced additional three papers. Full-text versions 
of these papers were obtained.      
Inclusion and exclusion criteria
The obtained 32 full-text articles were evaluated based 
on the criteria described below. As the number of articles was 
limited, full texts papers were examined to ensure the relevance 
of the selected studies. The inclusion criteria were kept quite 
wide as studies examining different modes of exposure delivery 
are rather scarce. The inclusion criteria applied for papers in 
this systematic review were as follows:
• Written in English, German or Spanish
• Participants meet criteria for both PD and agoraphobia
• At least two different modes of exposure delivery are 
compared in the study
To reduce the bias that might occur if only studies written 
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in the English language are included, this systematic review 
also aimed to include studies published in English and Spanish. 
Excluded papers
Twenty-four papers were excluded from this review after 
full-text examination. Reasons for exclusion are detailed in 
Figure 1.   
RESuLTS
This section summarizes the findings of the reviewed 
papers and the analyses of their methodological strengths and 
weaknesses.
The process of excluding the papers at each stage is 
presented in Fgure 1.
Eight papers met the inclusion criteria. Two compared the 
effectiveness of therapist-led and self-directed IVE [59, 68]. 
One compared self-directed IVE and self-directed IE [69]. 
Two compared VRE and EIV [57–58]. Three papers compared 
VRE-enhanced CBT to standard CBT [70–72].      
Methodological Evaluation and main findings
The main methodological characteristics are presented in 
Table 1. 
DISCuSSION
The aim of this systematic review is to evaluate currently 
available research data on the influence of exposure method 
used in CBT for PDA on treatment outcomes. This section will 
discuss the findings of this review. Theoretical and clinical 
implications of the findings will be discussed as well, followed 
by the limitations of this review and suggestions for future 
research. 
Summary of findings
The papers included in this review compared two or 
more exposure methods in CBT treatments for PDA. Studies 
1–3 and 5 experimentally compared two or three exposure 
methods, while study 4 compared the implementation of 
exposure methods retrospectively. Papers 6–8 compared 
Figure 1. Flow chart showing the number of papers generated by each database search and the filtering process used to produce the final eight 
papers for review
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VRET-enhanced CBT to standard CBT for PDA.
In general, the reviewed papers found relatively few 
significant differences between the results produced by 
different exposure methods. A more detailed summary of the 
findings is provided below. 
Studies 1 and 2 experimentally compared two CBT 
treatment protocols, one comprising VRE and another one 
comprising traditional IVE. In both studies these were also 
compared to a WL control group. Study 1 found that both 
active treatments produced equal results at post-treatment on 
all PDA-specific measures (MI-alone, ACQ and BCQ), except 
PDSS, on which the in IVE group did significantly better, 
F(2,40)=8.293, p<0.001.
Study 2 found no significant differences between the 
two active conditions on any outcome measures at post-
treatment or 12-month follow-up. Between post-treatment 
and follow-up, participants in both active groups improved 
further on ACQ, F(1,22)=4.48, p<0.05; PDSS, F(1,22)=15.94, 
p<0.001; MS global impairment, F(1,21)=9.56, p<0.01; and 
CGI F(1,22)=6.14, p<0.05. Participants in both active groups 
maintained gains on all the other measures. 
Study 3 compared two CBT treatment protocols, one 
combining in vivo therapist-led and self-led exposure and 
another one employing in vivo self-led exposure only. This 
study found that at post-treatment patients in both active 
conditions had improved significantly more than WL control 
group on all measures, but patients in the T+ condition improved 
more on MI (t
335
=3.12, p=0.01) and CGI (z=1.76, p=0.039). 
At post-treatment, there were significantly more people in 
the T- group reporting no panic attacks in the previous week, 
than in the T+ group (47.2% vs. 58.0%), c2(1)=3.45, p=0.032, 
but the difference was not significant when controlling for 
baseline values. Furthermore, at 6-month follow-up, T+ group 
had continued to improve significantly (19.1% increase in 
participants with no panic attacks in the past week), while 
the T- group had not (0.7%), t
298
=3.26, p<0.001. At 24-month 
follow-up, the T+ groups did significantly better than T- group 
Key for abbreviations for measures used:
ACQ Anxious Cognitions Questionnaire [73] 
ASI Anxiety Sensitivity Index [74]
BDI Beck Depression Inventory [75]
BSQ Body Sensations Questionnaire [73]
CGI Clinical Global Impression [76]  
DES Dissociative Experience Scale [77]
ERS Expectancies Rating Scale [78]
FQ Fear Questionnaire [79]
FQ-Ag Fear Questionnaire, Agoraphobia Subscale [79] 
GAF Global Assessment of Functioning [80] 
HAS Hamilton Anxiety Rating Scale [81]
MS Maladjustment Scale [82] 
MI  Mobility Inventory [83] 
PAS Panic and Agoraphobia Scale [84] 
PBQ Panic Belief Questionnaire [85] 
PDSS  Panic Disorder Severity Scale [86] 
PPGAS Panic, Phobia and Generalised Anxiety Scale [87] 
SDS Sheehan Disability Scale [88]   
STAI State and Trait Anxiety Questionnaire [89] 
WSA Work and Social Adjustment Scale [90] 
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on agoraphobic avoidance (MI: difference in d=0.37), p<0.05). 
The percentage of patients who had achieved clinically 
significant change in panic and agoraphobia symptoms as 
measured by the PAS did not differ between the T+ and T- groups 
at FU-24. Neither T+ nor T- achieved further improvements on 
any measures between FU-6 and FU-24. Although both groups 
were able to maintain gains, the T+ group reported a significant 
worsening of symptoms on PAS (d=–0.34, p=0.019) and CGI 
(d=–0.66, p=0.006), whereas patients in T- condition reported 
worsening on MI (d=–0.21, p=0.03). 
Study 4 found that patients who engaged in both therapist-
led and self-directed IVE, achieved greater reduction in 
agoraphobic avoidance as measured by MI, than those who did 
not engage in IVE at all, t(71)=–3.06, p<0.01, or who engaged 
in self-led IVE only, t(71)=–2.11, p<0.05. Combined IVE was 
also associated with greater improvement on ACQ than no IVE, 
t(68)=–4.06, p<0.01. However, no differences in improvement 
on BSQ were identified. Combined therapist-led and patient-
led IE was found to be associated with greater reduction of 
MI scores than no IE, t(49)=–2.20, p<0.05. Combined IE was 
also more effective than only therapist-led IE in reducing MI 
scores: t(60)=–2.12, p<0.05 
Study 5 compared three different types of self-led exposure: 
interoceptive, in vivo, and combined. This study found that 
participants in all three groups did equally well on all outcome 
measures (ACQ, CGI, HAS, FQ, FQAg, BDI). There were no 
significant differences between the active treatment groups 
at post-treatment, or at 6-month and 12-month follow-up. 
Between post-treatment and 12-month follow-up patients in 
all three active treatment groups continued to improve on CGI 
and HAS. 
Studies 6, 7 and 8 looked at how VR exposure-based 
therapy compares to standard CBT. Study 6 found that both 
interventions produced equal results. However, this study 
failed to find statistically significant difference between the 
outcomes produced by the active treatment conditions and 
the WL control group at post-treatment, and 6-month and 
12-month follow-up. At post-treatment, 45.8% of the sample in 
the CBT group, 42.1% in the VRET group and 35% in the WL 
control group met criteria for significant improvement (50% 
or larger reduction on the FQ-Ag). This study found that CBT 
group had improved significantly more than VRET group at 
6-month follow-up on Disturbance Subscale of FQ and Phobia 
1 Subscale of PPGAS.   
Study 7 found that 12 sessions of CBT and 8 sessions of 
VRET produced equal results on FQ. Furthermore, participants 
in both groups reported no panic attacks at post-treatment. 
Study 8 compared standard 12-week CBT programme for 
PDA to 4 sessions of experiential cognitive therapy (ExCT) 
comprising standard CBT techniques and VR exposure. This 
study found that at post-treatment participants in both active 
conditions were doing equally well. However, at 6-month 
follow-up significantly more participants in the CBT group 
than in the ExCT group were no longer taking anxiolytic 
medication to manage their PDA (c2=8.47, p<0.05).
In summary, although in most cases different exposure 
methods produced similar results in the reviewed studies, some 
significant differences were uncovered. On several occasions, 
VRET was outperformed by more classical exposure methods. 
In study 1, IVE produced better outcomes than VRET on 
PDSS; in study 6, CBT comprising IE, exposure in imagination 
and structured self-exposure homework outperformed VRET 
on FQ and PPGAS at follow-up; in study 8, PCP comprising 
IVE did better than VRET-enhanced ExCT on PBQ at post 
and on number of participants who discontinued anxiolytic 
medication at 6-month follow-up.
In addition, combination of therapist-led and self-led IVE 
was found to be superior to self-led exposure in studies 3 and 4. 
Participants in the therapist-assisted group in study 3 achieved 
better results on MI and CGI at post-treatment, and on HAS at 
6-months follow-up. Similarly, study 4 found that combined 
(therapist-led and self-led) IE was superior to therapist-led IE 
only, while combined IVE was superior to self-led IVE only. 
Implications for clinical practice and theory 
development 
The reviewed studies generally report positive outcomes 
and large effect sizes, supporting the notion that CBT treatments 
comprising exposure techniques are efficacious in treatment of 
PDA. However, several authors have pointed out that exposure 
is not routinely used in clinical practice despite of the solid 
evidence supporting the safety and effectiveness of these 
methods [91-93]. This is also mirrored in the reviewed studies, 
with experimental studies having allocated a considerably 
larger proportion of the therapy time to exposure assignments 
than the retrospective naturalistic study.     
IVE has accumulated a strong evidence base as key 
treatment ingredient for PDA, including positive outcomes at 
long-term follow-up (up to 14 years) [94, 95]. The efficacy of 
IVE, which sometimes exceeded that of other modalities, was 
further demonstrated in the reviewed studies. 
VRE has been demonstrated to produce promising 
outcomes in treatment of specific phobias [96-97]. The 
reviewed studies found that VRE can produce almost equally 
good results in PDA patients as IVE, both short- and longer-
term.  Furthermore, VRE was shown to be effective for severely 
impaired patients. However, the hopes that VRE could be a 
more acceptable alternative than IVE, which up to 30% of 
patients find too aversive [54], have not been confirmed in the 
reviewed studies. Page [98] criticised the research on VRET in 
anxiety disorders for small sample sizes. This was also the case 
in the reviewed studies. Therefore, the findings need to be to 
interpreted with caution and more research is indicated.
The findings in the reviewed studies indicated that 
therapist-assisted and self-led exposure produced almost 
equal outcomes, with therapist-assisted exposure being 
slightly superior in reducing agoraphobic avoidance. This is a 
promising finding in the context of low-intensity CBT, which 
can be delivered online or over the phone, and implies that 
the therapist is not able to participate in exposure assignments. 
At the same time, the findings suggest that whenever possible, 
incorporating therapist-assisted exposure in session might be 
beneficial, especially for reduction of agoraphobic avoidance, 
which has been demonstrated to predict long-term stability of 
treatment gains [99].   
Furthermore, participants in most reviewed studies 
engaged in several types of exposure across the conditions, 
which again might have contributed to the positive outcomes 
through the consolidation of learning in various contexts [25]. 
The evidence from the reviewed studies further support 
the effectiveness of exposure-based techniques for PDA. The 
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reviewed studies were conducted in seven different countries 
yet produced similar results, suggesting the universality of 
CBT based treatments. Similar conclusions were drawn by 
Kenardy et al. [100] in a study investigating the effectiveness 
of standard CBT for PD in Scotland and Australia. This study 
concluded that “treatment effectiveness is robust to cultural 
difference” (p. 1074). 
Summary of the methodological evaluation
The reviewed studies varied in their methodological 
quality. While studies 1 and 3 succeeded to control for most 
extraneous variables and compared two otherwise identical 
treatment packages where the only difference was the exposure 
method, the rest of the studies had some serious methodological 
problems. Study 2 did not provide any data on attrition and 
failed to report whether participants were encouraged to engage 
in exposure homework. Study 4 was a retrospective study, so it 
is not possible to draw any conclusions on causal effects of the 
interventions, as no extraneous variables had been controlled. 
In study 5 which studied effects of self-led exposure, all the 
participants received two sessions of therapist-led exposure 
first. This might have affected the patients’ ability to engage 
in self-led exposure later in treatment. In study 6, participants 
in the VRET condition were encouraged to regularly engage 
in self-led in vivo exposure between sessions, making it 
difficult to separate between the effects of VRET and self-led 
IVE. Similarly, in Study 7, participants who received VRET, 
were encouraged to engage in graded self-exposure between 
sessions, and each session started with the review of the 
homework. In contrast, participants in the CBT condition in 
this study did not receive in vivo exposure in sessions and 
the study did not provide any data on what kind of homework 
participants in this condition were asked to do. 
In study 8, the ExCT condition, which included VRE 
exposure, consisted of 4 sessions only, in contrast to the CBT 
condition which comprised 12 sessions. As the two conditions 
differed so greatly in the length of intervention, it is difficult 
to establish whether the relative poorer long-term outcomes 
in the ExCT group were the result of the specific components 
of the intervention, or its inadequate length. Furthermore, 
participants in ExCT condition underwent both IE and IVE 
in session, again making it difficult to distinguish between the 
effects of VRET and other types of exposure.
Sample sizes in the studies were also very different. Study 
3 was the biggest study and had 369 participants, while study 7 
had only 12. None of the studies provided a priori sample size 
calculations.    
In addition to that, the samples in the studies varied 
considerably in complexity. While studies 1, 5 and 7 excluded 
patients with the comorbid MDD, 37.7% of the patients in 
study 3 and 17% of the patients in study 4 were diagnosed with 
comorbid depression at baseline. Roy Byrne et al. [101] found 
that people with comorbid lifetime major depression reported 
a larger number of physiological symptoms during their panic 
attacks and that both current and lifetime depression-panic 
comorbidity was associated with more severe, persistent and 
disabling illness.
In summary, criticisms of the reviewed studies include 
small sample sizes and possible lack of statistical power, 
scarcity of long-term follow-up data and limited control of 
confounding variables.  
Overall the findings of this systematic review demonstrate 
that various exposure-based methods produce positive and 
similar short-term and longer-term outcomes, although 
IVE, especially when administered both in session and as 
homework, may produce superior outcomes. However, 
these results should be interpreted with caution, as identified 
methodological weaknesses in a number of the reviewed 
studies make it difficult to draw robust conclusions. Further 
high-quality research is clearly needed.  
Limitations of this review
When interpreting the findings of this systematic review 
it is important to take its limitations into account. The quality 
of search has a crucial effect on the validity of the results of 
a systematic review [102]. Attempts were made to identify 
relevant papers by searching a high variety of databases and 
examining the reference lists of papers and meta-analyses. 
However, there is always a risk of papers being missed. 
In addition, although this review aimed to include papers 
published in English, German and Spanish, the search was 
performed only in the international databases predominantly 
containing English language papers. Therefore, German or 
Spanish papers could still have been missed. Furthermore, 
there may be some relevant research published in other 
languages that was not addressed. 
The studies were identified and reviewed only by the 
author, leading to potential risk for subjectivity. Furthermore, 
all the included papers were published in peer-reviewed 
journals, which are more likely to publish papers reporting 
promising treatment effects [102]. 
Suggestions for future research
Future research should aim to study long-term outcomes 
produced by various exposure methods. More high-quality 
research is needed to establish the effectiveness of virtual 
reality exposure in the treatment of PDA. Only one reviewed 
study reported how much time participants spent engaging in 
exposure. The question of how much exposure is needed to 
produce satisfactory outcomes could also be addressed in future 
research. Furthermore, non-responders remain an important 
issue. One way of addressing this challenge could be to look at 
whether individuals who do not respond to a particular method 
of exposure would respond to exposure exercises delivered 
through a different modality.   
CONCLuSION
Although CBT is the psychological treatment of choice for 
PDA, and exposure is an integral component of most CBT for 
PDA protocols, surprisingly few studies have looked little at 
how different modalities of exposure delivery compare to one 
another.  
Although the currently available data suggests that different 
exposure modalities tend to produce similar results, there are 
some indications of IVE possibly producing somewhat superior 
outcomes to VRE and exposure delivered both in session and 
as homework leading to a larger reduction in agoraphobic 
avoidance than only self-led exposure. However, due to very 
small number of studies and a number of methodological issues 
in particular regarding non-inferiority trials, more high-quality 
research with larger samples is clearly needed.   
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